Supera-CBD
Epilepsy
Key Facts
About TNF Pharmaceuticals
TNF Pharmaceuticals is a clinical-stage biotech focused on modulating immunometabolic pathways to treat autoimmune, inflammatory, and age-related diseases. Its core achievement is advancing MYMD-1®, an oral TNF-alpha inhibitor with Phase 2 success in sarcopenia, into planned Phase 3 trials, with a parallel program in synthetic cannabinoids. In a significant strategic pivot, the company has licensed exclusive global rights to a light-speed computing accelerator for cryptocurrency, signaling a major diversification beyond its traditional biopharma focus. This move aims to create a dual-track business model combining clinical development with high-tech commercialization.
View full company profileAbout TNF Pharmaceuticals
TNF Pharmaceuticals is a clinical-stage biotech focused on modulating immunometabolic pathways to treat autoimmune, inflammatory, and age-related diseases. Its core achievement is advancing MYMD-1®, an oral TNF-alpha inhibitor with Phase 2 success in sarcopenia, into planned Phase 3 trials, with a parallel program in synthetic cannabinoids. In a significant strategic pivot, the company has licensed exclusive global rights to a light-speed computing accelerator for cryptocurrency, signaling a major diversification beyond its traditional biopharma focus. This move aims to create a dual-track business model combining clinical development with high-tech commercialization.
View full company profileAbout TNF Pharmaceuticals
TNF Pharmaceuticals is a clinical-stage biotech focused on modulating immunometabolic pathways to treat autoimmune, inflammatory, and age-related diseases. Its core achievement is advancing MYMD-1®, an oral TNF-alpha inhibitor with Phase 2 success in sarcopenia, into planned Phase 3 trials, with a parallel program in synthetic cannabinoids. In a significant strategic pivot, the company has licensed exclusive global rights to a light-speed computing accelerator for cryptocurrency, signaling a major diversification beyond its traditional biopharma focus. This move aims to create a dual-track business model combining clinical development with high-tech commercialization.
View full company profileTherapeutic Areas
Other Epilepsy Drugs
| Drug | Company | Phase |
|---|---|---|
| ADX71149 (mGlu2 PAM) | Addex Therapeutics | Phase 2 |
| TRV045 | Trevena | Phase 1 |
| SAGE-324 | Sage Therapeutics | Preclinical |
| Motpoly XR™ | Aucta Pharmaceuticals | Not Specified (Likely Phase 3/NDA) |
| ADB-104 | Adolore BioTherapeutics | Pre-clinical |
| Not Publicly Disclosed | Cerecin | Phase 2 |
| eTNS Platform | NeuroSigma | Unknown |
| NPT 2042 | NeuroPro Therapeutics | Phase 2 |
| Spritam (levetiracetam) | Aprecia Pharmaceuticals | Approved |
| Perampanel | Ark Diagnostics | In Development |
| NeuroAccess Platform | Cordance Medical | Pre-clinical/Research |
| Epilepsy Program | Current Surgical | Research |